LABELS · 4bcdd632-5be8-4750-a3b6-59a2b6d8f130

Dantrium

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-08-25
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

Dantrium (dantrolene sodium) has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to Dantrium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medication(s) in addition to Dantrium (dantrolene sodium). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving Dantrium. However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see Geriatric Use subsection). Dantrium should be used only in conjunction with appropriate monitoring of hepatic function including frequent determination of SGOT or SGPT. If no observable benefit is derived from the administration of Dantrium after a total of 45 days, therapy should be discontinued. The lowest possible effective dose for the individual patient should be prescribed.

Indications and usage: exact source text

INDICATIONS AND USAGE In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia: Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

Full extracted label fields

application numbers

NDA017443

boxed warning exact

Dantrium (dantrolene sodium) has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to Dantrium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medication(s) in addition to Dantrium (dantrolene sodium). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving Dantrium. However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see Geriatric Use subsection). Dantrium should be used only in conjunction with appropriate monitoring of hepatic function including frequent determination of SGOT or SGPT. If no observable benefit is derived from the administration of Dantrium after a total of 45 days, therapy should be discontinued. The lowest possible effective dose for the individual patient should be prescribed.

brand names

Dantrium

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b

generic names

DANTROLENE SODIUM

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

indications and usage exact

INDICATIONS AND USAGE In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia: Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

indications and usage tables exact

is original packager

true

manufacturer names

Par Health USA, LLC

matched search terms

malignant

package ndcs

42023-124-01
42023-125-01
42023-126-01

product ndcs

42023-124
42023-125
42023-126

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

856652
856654
856656
856658
856660
856662

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA017443

brand names

Dantrium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 442
end exclusive: true
exact text: INDICATIONS AND USAGE In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of sp
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 0

current approval status

not_reconciled

duplicate text group

dup-6061d076199e02821ab3

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-09a2da848028a8799410

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

end: 66
end exclusive: true
exact text: is indicated
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 54

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 242
end exclusive: true
exact text: INDICATIONS AND USAGE In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis).
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 566
end exclusive: true
exact text: : Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm result
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 43

current approval status

not_reconciled

duplicate text group

dup-1c654787086c985d5ac6

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-ba5f8f31678318eaa4ef

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

context exact
fit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity.
kind
biomarker
polarity
not_inferred
span
end
365
end exclusive
true
exact text
retarded by the sequelae of spasticity
label id
4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start
327

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 366
end exclusive: true
exact text: It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 243

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 691
end exclusive: true
exact text: (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADM
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 167

current approval status

not_reconciled

duplicate text group

dup-4fcd479b334cc0ffd736

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-cf12644165bd9d8b415c

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 491
end exclusive: true
exact text: Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 367

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · limitation of use

application numbers

NDA017443

brand names

Dantrium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 795
end exclusive: true
exact text: functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to res
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 292

current approval status

not_reconciled

duplicate text group

dup-39818b5da0f76d2be375

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-531c16ef0e1dedd07422

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 595
end exclusive: true
exact text: Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 492

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1054
end exclusive: true
exact text: mably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 396

current approval status

not_reconciled

duplicate text group

dup-2f27c724fba88b8a6195

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-da54a19a501a87e92ef9

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 854
end exclusive: true
exact text: If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 596

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1149
end exclusive: true
exact text: dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a perio
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 655

current approval status

not_reconciled

duplicate text group

dup-be78d29cf42a945eb2b9

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-146cc64ce7985ae83e15

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 949
end exclusive: true
exact text: Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 855

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1308
end exclusive: true
exact text: severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to con
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 750

current approval status

not_reconciled

duplicate text group

dup-b80d609a2f64b69d335e

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-17460f5219fc43e2940e

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1108
end exclusive: true
exact text: In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 950

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1490
end exclusive: true
exact text: sticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disa
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 909

current approval status

not_reconciled

duplicate text group

dup-ee8a5d65dadabd54aeb4

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-408002f412fc37133f0e

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1290
end exclusive: true
exact text: Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1109

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1923
end exclusive: true
exact text: endance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia: Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperther
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1091

current approval status

not_reconciled

duplicate text group

dup-bd576705a20f3c81c65e

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-3cbd0d8295d8798215dd

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1723
end exclusive: true
exact text: A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1291

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · positive indication candidate

application numbers

NDA017443

brand names

Dantrium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2186
end exclusive: true
exact text: r permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia: Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mech
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1524

current approval status

not_reconciled

duplicate text group

dup-e73c35e2bb53eda7088b

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-5109582895b277c7249c

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

end: 1782
end exclusive: true
exact text: is also indicated
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1765

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1986
end exclusive: true
exact text: In Malignant Hyperthermia: Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1724

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2539
end exclusive: true
exact text: peratively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1787

current approval status

not_reconciled

duplicate text group

dup-0270ce1a2d77aa38d0cf

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-bad07723fba46ad89514

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2398
end exclusive: true
exact text: Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 1987

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA017443

brand names

Dantrium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2539
end exclusive: true
exact text: ompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 2199

current approval status

not_reconciled

duplicate text group

dup-5302d6569ce7f147dcc1

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-9eb6da883529969738ca

label id

4bcdd632-5be8-4750-a3b6-59a2b6d8f130

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2539
end exclusive: true
exact text: Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 4bcdd632-5be8-4750-a3b6-59a2b6d8f130
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af3aa4e61a68595b457c38997a234964ffa122bbb8ec8be2b0edd58d81bffb96
start: 2399

source url

https://api.fda.gov/drug/label.json?search=id%3A%224bcdd632-5be8-4750-a3b6-59a2b6d8f130%22

spl effective date

2026-08-25

spl set id

57b4eec1-49e1-432c-95ae-0fe36e32d64b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice